Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study
Shengyu Zhou, Changgong Zhang, Guowen Wang, Jun Qian, Gang Huang, Jiaqiang Wang, Suxia Luo, Youhua Zhu, Qingyuan Zhang, Ting Wei, Yongsheng Li, Zhendong Li, Dongyuan Zhu, Huarong Zhao, Meiyu Fang, Shoubing Zhou, Qing Xu, Yu Chen, Kejun Nan, Jiuwei Cui, Xueqiang Zhu, Yanchun Gong, Yong Wu, Xiaojuan Lai, Yuankai Shi · 2026
Read Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study by Shengyu Zhou, Changgong Zhang, Guowen Wang, Jun Qian, Gang Huang, Jiaqiang Wang, Suxia Luo, Youhua Zhu, Qingyuan Zhang, Ting Wei, Yongsheng Li, Zhendong Li, Dongyuan Zhu, Huarong Zhao, Meiyu Fang, Shoubing Zhou, Qing Xu, Yu Chen, Kejun Nan, Jiuwei Cui, Xueqiang Zhu, Yanchun Gong, Yong Wu, Xiaojuan Lai, Yuankai Shi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13591854.txt.
Description
Shengyu Zhou leads a 2026 early trial of eratrectinib, a next generation drug for cancers carrying NTRK gene fusions. Such fusions switch on growth kinases, and first drugs against them work well until resistance blooms. The new drug was built to beat that resistance. Sixteen patients joined dose escalation, and 75 more with fusion positive tumors joined expansion groups at set doses.
Side effects hit most patients yet stayed manageable, with dizziness the most common and no treatment linked deaths. A mid dose was picked for the next phase. At that dose, seven in ten patients saw tumors shrink. Zhou and the team present the drug as a fresh option for this rare tumor group, pending larger trials.
Catalog record
| CREATOR | Shengyu Zhou, Changgong Zhang, Guowen Wang, Jun Qian, Gang Huang, Jiaqiang Wang, Suxia Luo, Youhua Zhu, Qingyuan Zhang, Ting Wei, Yongsheng Li, Zhendong Li, Dongyuan Zhu, Huarong Zhao, Meiyu Fang, Shoubing Zhou, Qing Xu, Yu Chen, Kejun Nan, Jiuwei Cui, Xueqiang Zhu, Yanchun Gong, Yong Wu, Xiaojuan Lai, Yuankai Shi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54017 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |